Literature DB >> 4698566

Parkinsonism treated with 3-O-methyldopa.

D B Calne, J L Reid, S D Vakil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4698566     DOI： 10.1002/cpt1973143386

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  9 in total

1.  Gout induced by L-dopa and decarboxylase inhibitors.

Authors:  D B Calne; J Fermaglich
Journal:  Postgrad Med J       Date:  1976-04       Impact factor: 2.401

2.  Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

Authors:  J R Bianchine; L Sunyapridakul
Journal:  Drugs       Date:  1973       Impact factor: 9.546

3.  The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

Authors:  S Bergmann; G Curzon; J Friedel; R B Godwin-Austen; C D Marsden; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

4.  Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.

Authors:  T Keränen; A Gordin; M Karlsson; K Korpela; P J Pentikäinen; H Rita; E Schultz; L Seppälä; T Wikberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Authors:  M Merello; A J Lees; R Webster; M Bovingdon; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

Review 6.  Concentration-effect relationship of levodopa in patients with Parkinson's disease.

Authors:  S Harder; H Baas; S Rietbrock
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

7.  Absorption, metabolism and distribution of (14C)-O-methyldopa and (14C)-L-dopa after oral administration to rats.

Authors:  L Rivera-Calimlim
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739

8.  Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.

Authors:  V V Myllylä; K A Sotaniemi; A Illi; K Suominen; T Keränen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.

Authors:  A Reches; D Jiang; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.